Aktienanalyse zu Telomir Pharmaceuticals Inc (TELO)TELOTelomir Pharmaceuticals Inc

Telomir Pharmaceuticals, Inc. is a biotechnology company developing small-molecule therapeutics designed to target epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The Company's lead candidate, Telomir-1 (Telomir-Zn), is an investigational therapy that has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, epigenetic regulation, mitochondrial function, and genomic stability. Telomir-1 is an oral small molecule metal ion regulator designed to extend telomere caps, maintain cellular balance, and combat oxidative stress, a key driver of aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 may help protect against age related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease, and Age-related Macular Degeneration (AMD), as well as Type 2 diabetes, breast cancer, and Alzheimer’s disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Telomir Pharmaceuticals Inc (TELO) is currently trading at $1.14, which is below its 200-day simple moving average of $1.279. The stock has a relative strength index (RSI) of 46.462, indicating it is neither overbought nor oversold. However, the company has reported consistent losses, with a net income of -$47,835,431 in Q2 2026 and a negative EPS of -0.79. The forward P/E ratio is 0, indicating no earnings expected in the near term. The stock has seen a year-to-date change of -14.93%, suggesting a downward trend. The main risk is the significant net loss reported, which could impact future performance. Overall, while there are some signs of potential recovery, the current financial performance and negative earnings trend suggest it may be prudent to hold off on buying until further positive developments occur.